Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David Christian Harmon, M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Liao Y, Sassi S, Halvorsen S, Feng Y, Shen J, Gao Y, Cote G, Choy E, Harmon D, Mankin H, Hornicek F, Duan Z. Author Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11. Sci Rep. 2018 Aug 09; 8(1):12107. PMID: 30093700.
    Citations:    Fields:    
  2. Wang H, Miao R, Jacobson A, Harmon D, Choy E, Hornicek F, Raskin K, Chebib I, DeLaney TF, Chen YE. Extraskeletal osteosarcoma: A large series treated at a single institution. Rare Tumors. 2018; 10:2036361317749651. PMID: 31508194.
    Citations:    
  3. Liao Y, Chen L, Feng Y, Shen J, Gao Y, Cote G, Choy E, Harmon D, Mankin H, Hornicek F, Duan Z. Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells. Oncotarget. 2017 May 02; 8(18):30276-30287. PMID: 28415820.
    Citations: 12     Fields:    Translation:HumansCells
  4. Bhatt AD, Jacobson A, Lee RY, Giraud C, Schwab JH, Hornicek FJ, Nielsen P, Choy E, Harmon D, DeLaney TF, Chen YE. High-Dose Proton Beam-Based Radiation Therapy in the Management of Extracranial Chondrosarcomas. Int J Part Ther. 2017; 3(3):373-381. PMID: 31772986.
    Citations: 1     
  5. Liao Y, Sassi S, Halvorsen S, Feng Y, Shen J, Gao Y, Cote G, Choy E, Harmon D, Mankin H, Hornicek F, Duan Z. Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11. Sci Rep. 2017 03 06; 7:43941. PMID: 28262798.
    Citations: 1     Fields:    Translation:HumansCells
  6. De Amorim Bernstein K, Liebsch N, Chen YL, Niemierko A, Schwab JH, Raskin K, Lozano-Calderon SA, Cote G, Harmon DC, Choy E, Haynes A, Mullen J, Hornicek FJ, DeLaney TF. Clinical outcomes for patients after surgery and radiation therapy for mesenchymal chondrosarcomas. J Surg Oncol. 2016 Dec; 114(8):982-986. PMID: 27790706.
    Citations: 2     Fields:    Translation:Humans
  7. Duan Z, Gao Y, Shen J, Choy E, Cote G, Harmon D, Bernstein K, Lozano-Calderon S, Mankin H, Hornicek FJ. miR-15b modulates multidrug resistance in human osteosarcoma in vitro and in vivo. Mol Oncol. 2017 02; 11(2):151-166. PMID: 28145098.
    Citations: 11     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
  8. Molina G, Hull MA, Chen YL, DeLaney TF, De Amorim Bernstein K, Choy E, Cote G, Harmon DC, Mullen JT, Haynes AB. Preoperative radiation therapy combined with radical surgical resection is associated with a lower rate of local recurrence when treating unifocal, primary retroperitoneal liposarcoma. J Surg Oncol. 2016 Dec; 114(7):814-820. PMID: 27634478.
    Citations: 5     Fields:    Translation:Humans
  9. Doltani D, Imran A, Saunders J, Harmon D. Who accompanies patients to the chronic pain clinic? Ir J Med Sci. 2017 Feb; 186(1):235-238. PMID: 27566184.
    Citations:    Fields:    Translation:Humans
  10. Gao Y, Liao Y, Shen JK, Feng Y, Choy E, Cote G, Harmon D, Mankin HJ, Hornicek FJ, Duan Z. Evaluation of P-glycoprotein (Pgp) expression in human osteosarcoma by high-throughput tissue microarray. J Orthop Res. 2016 09; 34(9):1606-12. PMID: 26790551.
    Citations: 4     Fields:    Translation:Humans
  11. Wang H, Jacobson A, Harmon DC, Choy E, Hornicek FJ, Raskin KA, Chebib IA, DeLaney TF, Chen YL. Prognostic factors in alveolar soft part sarcoma: A SEER analysis. J Surg Oncol. 2016 Apr; 113(5):581-6. PMID: 26804150.
    Citations: 6     Fields:    Translation:Humans
  12. Ye S, Zhang J, Shen J, Gao Y, Li Y, Choy E, Cote G, Harmon D, Mankin H, Gray NS, Hornicek FJ, Duan Z. NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (PGP1) function. Br J Pharmacol. 2016 Feb; 173(3):613-26. PMID: 26603906.
    Citations: 6     Fields:    Translation:HumansCells
  13. Liao Y, Feng Y, Shen J, Gao Y, Cote G, Choy E, Harmon D, Mankin H, Hornicek F, Duan Z. Clinical and biological significance of PIM1 kinase in osteosarcoma. J Orthop Res. 2016 07; 34(7):1185-94. PMID: 26687194.
    Citations: 5     Fields:    Translation:HumansCells
  14. Gao Y, Feng Y, Shen JK, Lin M, Choy E, Cote GM, Harmon DC, Mankin HJ, Hornicek FJ, Duan Z. CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma. Sci Rep. 2015 Jun 16; 5:11365. PMID: 26079799.
    Citations: 23     Fields:    Translation:HumansCells
  15. Yang X, Feng Y, Gao Y, Shen J, Choy E, Cote G, Harmon D, Zhang Z, Mankin H, Hornicek FJ, Duan Z. NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo. Gynecol Oncol. 2015 Apr; 137(1):134-42. PMID: 25677062.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  16. Choy E, Flamand Y, Balasubramanian S, Butrynski JE, Harmon DC, George S, Cote GM, Wagner AJ, Morgan JA, Sirisawad M, Mani C, Hornicek FJ, Duan Z, Demetri GD. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma. Cancer. 2015 Apr 15; 121(8):1223-30. PMID: 25536954.
    Citations: 16     Fields:    Translation:HumansCTClinical Trials
  17. Choy E, Butrynski JE, Harmon DC, Morgan JA, George S, Wagner AJ, D'Adamo D, Cote GM, Flamand Y, Benes CH, Haber DA, Baselga JM, Demetri GD. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer. 2014 Nov 05; 14:813. PMID: 25374341.
    Citations: 36     Fields:    Translation:HumansCTClinical Trials
  18. Duan Z, Zhang J, Ye S, Shen J, Choy E, Cote G, Harmon D, Mankin H, Hua Y, Zhang Y, Gray NS, Hornicek FJ. A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells. BMC Cancer. 2014 Sep 19; 14:681. PMID: 25236161.
    Citations: 4     Fields:    Translation:HumansCells
  19. Mullen JT, Hornicek FJ, Harmon DC, Raskin KA, Chen YL, Szymonifka J, Yeap BY, Choy E, DeLaney TF, Nielsen GP. Prognostic significance of treatment-induced pathologic necrosis in extremity and truncal soft tissue sarcoma after neoadjuvant chemoradiotherapy. Cancer. 2014 Dec 01; 120(23):3676-82. PMID: 25081640.
    Citations: 13     Fields:    Translation:Humans
  20. Mankin HJ, Mankin KP, Harmon DC. Liposarcoma: a soft tissue tumor with many presentations. Musculoskelet Surg. 2014 Dec; 98(3):171-7. PMID: 25047632.
    Citations: 3     Fields:    Translation:Humans
  21. Yang X, Yang P, Shen J, Osaka E, Choy E, Cote G, Harmon D, Zhang Z, Mankin H, Hornicek FJ, Duan Z. Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925. Br J Cancer. 2014 Jun 10; 110(12):2896-904. PMID: 24853187.
    Citations: 15     Fields:    Translation:HumansCells
  22. Shen JK, Cote GM, Choy E, Yang P, Harmon D, Schwab J, Nielsen GP, Chebib I, Ferrone S, Wang X, Wang Y, Mankin H, Hornicek FJ, Duan Z. Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res. 2014 Jul; 2(7):690-698. PMID: 24866169.
    Citations: 59     Fields:    Translation:HumansCells
  23. DeLaney TF, Liebsch NJ, Pedlow FX, Adams J, Weyman EA, Yeap BY, Depauw N, Nielsen GP, Harmon DC, Yoon SS, Chen YL, Schwab JH, Hornicek FJ. Long-term results of Phase II study of high dose photon/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas. J Surg Oncol. 2014 Aug; 110(2):115-22. PMID: 24752878.
    Citations: 36     Fields:    Translation:HumansCTClinical Trials
  24. Guo S, Lopez-Marquez H, Fan KC, Choy E, Cote G, Harmon D, Nielsen GP, Yang C, Zhang C, Mankin H, Hornicek FJ, Borger DR, Duan Z. Synergistic effects of targeted PI3K signaling inhibition and chemotherapy in liposarcoma. PLoS One. 2014; 9(4):e93996. PMID: 24695632.
    Citations: 7     Fields:    Translation:HumansCells
  25. Duan Z, Shen J, Yang X, Yang P, Osaka E, Choy E, Cote G, Harmon D, Zhang Y, Nielsen GP, Spentzos D, Mankin H, Hornicek F. Prognostic significance of miRNA-1 (miR-1) expression in patients with chordoma. J Orthop Res. 2014 May; 32(5):695-701. PMID: 24501096.
    Citations: 15     Fields:    Translation:HumansCells
  26. George S, Feng Y, Manola J, Nucci MR, Butrynski JE, Morgan JA, Ramaiya N, Quek R, Penson RT, Wagner AJ, Harmon D, Demetri GD, Krasner C. Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors. Cancer. 2014 Mar 01; 120(5):738-43. PMID: 24222211.
    Citations: 18     Fields:    Translation:HumansCTClinical Trials
  27. Jia B, Choy E, Cote G, Harmon D, Ye S, Kan Q, Mankin H, Hornicek F, Duan Z. Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells. Cancer Lett. 2014 Jan 01; 342(1):104-12. PMID: 24007862.
    Citations: 21     Fields:    Translation:HumansCells
  28. Mullen JT, DeLaney TF, Rosenberg AE, Le L, Iafrate AJ, Kobayashi W, Szymonifka J, Yeap BY, Chen YL, Harmon DC, Choy E, Yoon SS, Raskin KA, Hornicek FJ, Nielsen GP. ß-Catenin mutation status and outcomes in sporadic desmoid tumors. Oncologist. 2013; 18(9):1043-9. PMID: 23960186.
    Citations: 23     Fields:    Translation:Humans
  29. Kamran SC, Pendergraft WF, Harmon DC, Rubin MF. Ifosfamide-induced Fanconi syndrome and desmopressin-responsive nephrogenic diabetes insipidus. Am J Med. 2013 Jul; 126(7):e7-8. PMID: 23684064.
    Citations: 1     Fields:    Translation:Humans
  30. Garrett LA, Harmon DC, Schorge JO. Embryonal rhabdomyosarcoma of the uterine corpus. J Clin Oncol. 2013 Feb 01; 31(4):e48-50. PMID: 23248250.
    Citations: 1     Fields:    Translation:Humans
  31. Mankin HJ, Hornicek FJ, DeLaney TF, Harmon DC, Schiller AL. Pleomorphic spindle cell sarcoma (PSCS) formerly known as malignant fibrous histiocytoma (MFH): a complex malignant soft-tissue tumor. Musculoskelet Surg. 2012 Dec; 96(3):171-7. PMID: 23129168.
    Citations: 2     Fields:    Translation:HumansCells
  32. Dunn GP, Spiliopoulos K, Plotkin SR, Hornicek FJ, Harmon DC, Delaney TF, Williams Z. Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1. J Neurosurg. 2013 Jan; 118(1):142-8. PMID: 23101443.
    Citations: 11     Fields:    Translation:Humans
  33. Look Hong NJ, Hornicek FJ, Harmon DC, Choy E, Chen YL, Yoon SS, Nielsen GP, Szymonifka J, Yeap BY, DeLaney TF, Mullen JT. Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: a 10-year single institution retrospective study. Eur J Cancer. 2013 Mar; 49(4):875-83. PMID: 23092789.
    Citations: 14     Fields:    Translation:HumansCTClinical Trials
  34. Mullen JT, Delaney TF, Kobayashi WK, Szymonifka J, Yeap BY, Chen YL, Rosenberg AE, Harmon DC, Choy E, Yoon SS, Raskin KA, Petur Nielsen G, Hornicek FJ. Desmoid tumor: analysis of prognostic factors and outcomes in a surgical series. Ann Surg Oncol. 2012 Dec; 19(13):4028-35. PMID: 22965569.
    Citations: 26     Fields:    Translation:Humans
  35. Duan Z, Zhang J, Choy E, Harmon D, Liu X, Nielsen P, Mankin H, Gray NS, Hornicek FJ. Systematic kinome shRNA screening identifies CDK11 (PITSLRE) kinase expression is critical for osteosarcoma cell growth and proliferation. Clin Cancer Res. 2012 Sep 01; 18(17):4580-8. PMID: 22791884.
    Citations: 26     Fields:    Translation:HumansAnimalsCells
  36. Tariq Z, Ghose A, Sofi A, Mohamed I, Harmon D. Metastatic renal extraskeletal Ewing sarcoma in complete remission for the last 8 years. Am J Ther. 2012 May; 19(3):120-1. PMID: 20535010.
    Citations: 1     Fields:    Translation:Humans
  37. Kane JM, Harris J, Kraybill WG, Harmon DC, Ettinger DS, Lucas DR, Delaney TF, Wang D, Curran WJ, Eisenberg BL. Thromboembolic Events Associated with Thalidomide and Multimodality Therapy for Soft Tissue Sarcomas: Results of RTOG 0330. Sarcoma. 2012; 2012:659485. PMID: 22619566.
    Citations:    
  38. Liu X, Nielsen GP, Rosenberg AE, Waterman PR, Yang W, Choy E, Sassi S, Yang S, Harmon DC, Yang C, Schwab JH, Kobayashi E, Mankin HJ, Xavier R, Weissleder R, Duan Z, Hornicek FJ. Establishment and characterization of a novel chordoma cell line: CH22. J Orthop Res. 2012 Oct; 30(10):1666-73. PMID: 22504929.
    Citations: 11     Fields:    Translation:HumansAnimalsCells
  39. Look Hong NJ, Pandalai PK, Hornick JL, Shekar PS, Harmon DC, Chen YL, Butrynski JE, Baldini EH, Raut CP. Cardiac angiosarcoma management and outcomes: 20-year single-institution experience. Ann Surg Oncol. 2012 Aug; 19(8):2707-15. PMID: 22476752.
    Citations: 19     Fields:    Translation:HumansCTClinical Trials
  40. Duan Z, Li X, Huang H, Yuan W, Zheng SL, Liu X, Zhang Z, Choy E, Harmon D, Mankin H, Hornicek F. Synthesis and evaluation of (2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (NSC23925) isomers to reverse multidrug resistance in cancer. J Med Chem. 2012 Apr 12; 55(7):3113-21. PMID: 22400811.
    Citations: 7     Fields:    Translation:HumansAnimalsCells
  41. Tariq Z, Ghose A, Bawany MZ, Saeed B, Mohamed I, Harmon D. A case report of complete remission of pulmonary metastases from epithelioid sarcoma to navelbine chemotherapy. Am J Ther. 2012 Mar; 19(2):e95-7. PMID: 20634676.
    Citations: 3     Fields:    Translation:Humans
  42. Fox E, Patel S, Wathen JK, Schuetze S, Chawla S, Harmon D, Reinke D, Chugh R, Benjamin RS, Helman LJ. Phase II Study of Sequential Gemcitabine Followed by Docetaxel for Recurrent Ewing Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma: Results of Sarcoma Alliance for Research Through Collaboration Study 003. Oncologist. 2012; 17(3):321-e329. PMID: 22665455.
    Citations:    
  43. Fox E, Patel S, Wathen JK, Schuetze S, Chawla S, Harmon D, Reinke D, Chugh R, Benjamin RS, Helman LJ. Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003. Oncologist. 2012; 17(3):321. PMID: 22363068.
    Citations: 25     Fields:    Translation:HumansCTClinical Trials
  44. Mullen JT, Kobayashi W, Wang JJ, Harmon DC, Choy E, Hornicek FJ, Rosenberg AE, Chen YL, Spiro IJ, DeLaney TF. Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large, extremity soft tissue sarcomas. Cancer. 2012 Aug 01; 118(15):3758-65. PMID: 22180344.
    Citations: 21     Fields:    Translation:Humans
  45. Choy E, Hornicek F, MacConaill L, Harmon D, Tariq Z, Garraway L, Duan Z. High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes. Cancer. 2012 Jun 01; 118(11):2905-14. PMID: 22006429.
    Citations: 24     Fields:    Translation:HumansCells
  46. Duan Z, Choy E, Harmon D, Liu X, Susa M, Mankin H, Hornicek F. MicroRNA-199a-3p is downregulated in human osteosarcoma and regulates cell proliferation and migration. . 2011 Aug; 10(8):1337-45. PMID: 21666078.
    Citations: 94     Translation:HumansCells
  47. Liu X, Choy E, Harmon D, Yang S, Yang C, Mankin H, Hornicek FJ, Duan Z. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo. Anticancer Drugs. 2011 Jun; 22(5):444-53. PMID: 21399492.
    Citations: 11     Fields:    Translation:HumansAnimalsCells
  48. Ciernik IF, Niemierko A, Harmon DC, Kobayashi W, Chen YL, Yock TI, Ebb DH, Choy E, Raskin KA, Liebsch N, Hornicek FJ, Delaney TF. Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma. Cancer. 2011 Oct 01; 117(19):4522-30. PMID: 21448934.
    Citations: 27     Fields:    Translation:Humans
  49. Liu X, Choy E, Hornicek FJ, Yang S, Yang C, Harmon D, Mankin H, Duan Z. ROCK1 as a potential therapeutic target in osteosarcoma. J Orthop Res. 2011 Aug; 29(8):1259-66. PMID: 21387396.
    Citations: 32     Fields:    Translation:HumansCells
  50. Yoon SS, Duda DG, Karl DL, Kim TM, Kambadakone AR, Chen YL, Rothrock C, Rosenberg AE, Nielsen GP, Kirsch DG, Choy E, Harmon DC, Hornicek FJ, Dreyfuss J, Ancukiewicz M, Sahani DV, Park PJ, Jain RK, Delaney TF. Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):1081-90. PMID: 20932656.
    Citations: 25     Fields:    Translation:HumansCTClinical Trials
  51. Kraybill WG, Harris J, Spiro IJ, Ettinger DS, DeLaney TF, Blum RH, Lucas DR, Harmon DC, Letson GD, Eisenberg B. Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. Cancer. 2010 Oct 01; 116(19):4613-21. PMID: 20572040.
    Citations: 23     Fields:    Translation:HumansCTClinical Trials
  52. Yoon SS, Chen YL, Kirsch DG, Maduekwe UN, Rosenberg AE, Nielsen GP, Sahani DV, Choy E, Harmon DC, DeLaney TF. Proton-beam, intensity-modulated, and/or intraoperative electron radiation therapy combined with aggressive anterior surgical resection for retroperitoneal sarcomas. Ann Surg Oncol. 2010 Jun; 17(6):1515-29. PMID: 20151216.
    Citations: 23     Fields:    Translation:Humans
  53. Lane AM, Egan KM, Harmon D, Holbrook A, Munzenrider JE, Gragoudas ES. Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis. Ophthalmology. 2009 Nov; 116(11):2206-12. PMID: 19744725.
    Citations: 16     Fields:    Translation:HumansCTClinical Trials
  54. Duan Z, Choy E, Harmon D, Yang C, Ryu K, Schwab J, Mankin H, Hornicek FJ. ZNF93 increases resistance to ET-743 (Trabectedin; Yondelis) and PM00104 (Zalypsis) in human cancer cell lines. PLoS One. 2009 Sep 09; 4(9):e6967. PMID: 19742314.
    Citations: 7     Fields:    Translation:HumansCells
  55. Duan Z, Choy E, Harmon D, Yang C, Ryu K, Schwab J, Mankin H, Hornicek FJ. Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines. . 2009 Aug; 8(8):2122-30. PMID: 19638450.
    Citations: 32     Translation:HumansCells
  56. Schwab J, Antonescu C, Boland P, Healey J, Rosenberg A, Nielsen P, Iafrate J, Delaney T, Yoon S, Choy E, Harmon D, Raskin K, Yang C, Mankin H, Springfield D, Hornicek F, Duan Z. Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordoma. Anticancer Res. 2009 Jun; 29(6):1867-71. PMID: 19528441.
    Citations: 25     Fields:    Translation:HumansCells
  57. George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, Harmon DC, Bhuchar G, O'Mara MM, D'Adamo DR, Morgan J, Schwartz GK, Wagner AJ, Butrynski JE, Demetri GD, Keohan ML. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009 Jul 01; 27(19):3154-60. PMID: 19451429.
    Citations: 92     Fields:    Translation:HumansCTClinical Trials
  58. Maduekwe UN, Hornicek FJ, Springfield DS, Raskin KA, Harmon DC, Choy E, Rosenberg AE, Nielsen GP, DeLaney TF, Chen YL, Ott MJ, Yoon SS. Role of sentinel lymph node biopsy in the staging of synovial, epithelioid, and clear cell sarcomas. Ann Surg Oncol. 2009 May; 16(5):1356-63. PMID: 19259743.
    Citations: 10     Fields:    Translation:Humans
  59. Xu M, Du S, Wang J, Yu ZP, Harmon DL, Yao JH. Influence of rumen escape starch on pancreatic exocrine secretion of goats. J Anim Physiol Anim Nutr (Berl). 2009 Feb; 93(1):122-9. PMID: 19386016.
    Citations:    Fields:    Translation:Animals
  60. DeLaney TF, Liebsch NJ, Pedlow FX, Adams J, Dean S, Yeap BY, McManus P, Rosenberg AE, Nielsen GP, Harmon DC, Spiro IJ, Raskin KA, Suit HD, Yoon SS, Hornicek FJ. Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys. 2009 Jul 01; 74(3):732-9. PMID: 19095372.
    Citations: 44     Fields:    Translation:HumansCTClinical Trials
  61. Kane Iii JM, Harris J, Kraybill WG, Harmon DC, Ettinger DS, Lucas DR, DeLaney TF, Wang D, Curran WJ, Eisenberg BL. RTOG 0330: A pilot phase II study of preoperative radiation therapy/thalidomide for low-grade primary soft tissue sarcoma or preoperative MAID/thalidomide/radiation therapy for high/intermediate grade primary soft tissue sarcoma of the extremity or body wall. J Clin Oncol. 2008 May 20; 26(15_suppl):10536. PMID: 27948544.
    Citations:    
  62. Keohan ML, Morgan JA, D'Adamo DR, Harmon D, Butrynski JE, Wagner AJ, Schwartz GK, Maki RG, Demetri GD, George S. Continuous daily dosing (CDD) of sunitinib (SU) in patients with metastatic soft tissue sarcomas (STS) other than GIST: Results of a phase II trial. J Clin Oncol. 2008 May 20; 26(15_suppl):10533. PMID: 27948539.
    Citations:    
  63. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, Fanucchi M, Harmon DC, Schuetze SM, Reinke D, Thall PF, Benjamin RS, Baker LH, Hensley ML. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol. 2007 Jul 01; 25(19):2755-63. PMID: 17602081.
    Citations: 187     Fields:    Translation:HumansCTClinical Trials
  64. Dileo P, Morgan JA, Zahrieh D, Desai J, Salesi JM, Harmon DC, Quigley MT, Polson K, Demetri GD, George S. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. Cancer. 2007 May 01; 109(9):1863-9. PMID: 17385194.
    Citations: 22     Fields:    Translation:HumansCTClinical Trials
  65. Delaney TF, Kepka L, Goldberg SI, Hornicek FJ, Gebhardt MC, Yoon SS, Springfield DS, Raskin KA, Harmon DC, Kirsch DG, Mankin HJ, Rosenberg AE, Nielsen GP, Suit HD. Radiation therapy for control of soft-tissue sarcomas resected with positive margins. Int J Radiat Oncol Biol Phys. 2007 Apr 01; 67(5):1460-9. PMID: 17394945.
    Citations: 41     Fields:    Translation:Humans
  66. Abraham JA, Hornicek FJ, Kaufman AM, Harmon DC, Springfield DS, Raskin KA, Mankin HJ, Kirsch DG, Rosenberg AE, Nielsen GP, Desphpande V, Suit HD, DeLaney TF, Yoon SS. Treatment and outcome of 82 patients with angiosarcoma. Ann Surg Oncol. 2007 Jun; 14(6):1953-67. PMID: 17356953.
    Citations: 66     Fields:    Translation:Humans
  67. Kraybill WG, Harris J, Spiro IJ, Ettinger DS, DeLaney TF, Blum RH, Lucas DR, Harmon DC, Letson GD, Eisenberg B. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. J Clin Oncol. 2006 Feb 01; 24(4):619-25. PMID: 16446334.
    Citations: 51     Fields:    Translation:HumansCTClinical Trials
  68. Garcia-Carbonero R, Supko JG, Maki RG, Manola J, Ryan DP, Harmon D, Puchalski TA, Goss G, Seiden MV, Waxman A, Quigley MT, Lopez T, Sancho MA, Jimeno J, Guzman C, Demetri GD. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol. 2005 Aug 20; 23(24):5484-92. PMID: 16110008.
    Citations: 49     Fields:    Translation:HumansCTClinical Trials
  69. Mohiuddin MM, Harmon DC, Delaney TF. Severe acute enteritis in a multiple myeloma patient receiving bortezomib and spinal radiotherapy: case report. J Chemother. 2005 Jun; 17(3):343-6. PMID: 16038531.
    Citations: 2     Fields:    Translation:HumansPHPublic Health
  70. Mankin HJ, Hornicek FJ, Rosenberg AE, Harmon DC, Gebhardt MC. Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res. 2004 Dec; (429):286-91. PMID: 15577500.
    Citations: 55     Fields:    Translation:Humans
  71. Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, Harmon D, Ryan DP, Goss G, Quigley T, Van den Abbeele AD, Silverman SG, Connors S, Folkman J, Fletcher CD, Demetri GD. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res. 2004 Sep 01; 10(17):5732-40. PMID: 15355900.
    Citations: 25     Fields:    Translation:HumansCTClinical Trials
  72. Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, Quigley MT, Merriam P, Canniff J, Goss G, Matulonis U, Maki RG, Lopez T, Puchalski TA, Sancho MA, Gomez J, Guzman C, Jimeno J, Demetri GD. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol. 2004 Apr 15; 22(8):1480-90. PMID: 15084621.
    Citations: 82     Fields:    Translation:HumansCTClinical Trials
  73. Laverdiere C, Kolb EA, Supko JG, Gorlick R, Meyers PA, Maki RG, Wexler L, Demetri GD, Healey JH, Huvos AG, Goorin AM, Bagatell R, Ruiz-Casado A, Guzman C, Jimeno J, Harmon D. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer. 2003 Aug 15; 98(4):832-40. PMID: 12910529.
    Citations: 24     Fields:    Translation:HumansCTClinical Trials
  74. DeLaney TF, Spiro IJ, Suit HD, Gebhardt MC, Hornicek FJ, Mankin HJ, Rosenberg AL, Rosenthal DI, Miryousefi F, Ancukiewicz M, Harmon DC. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys. 2003 Jul 15; 56(4):1117-27. PMID: 12829150.
    Citations: 71     Fields:    Translation:HumansCTClinical Trials
  75. Harmon D, Rozario C, Lowe D. Nitrous oxide/oxygen mixture and the prevention of pain during injection of propofol. Eur J Anaesthesiol. 2003 Feb; 20(2):158-61. PMID: 12622502.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  76. Puchalski TA, Ryan DP, Garcia-Carbonero R, Demetri GD, Butkiewicz L, Harmon D, Seiden MV, Maki RG, Lopez-Lazaro L, Jimeno J, Guzman C, Supko JG. Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol. 2002 Oct; 50(4):309-19. PMID: 12357306.
    Citations: 17     Fields:    Translation:HumansCTClinical Trials
  77. Treon SP, Pilarski LM, Belch AR, Kelliher A, Preffer FI, Shima Y, Mitsiades CS, Mitsiades NS, Szczepek AJ, Ellman L, Harmon D, Grossbard ML, Anderson KC. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother. 2002 Jan-Feb; 25(1):72-81. PMID: 11924912.
    Citations: 29     Fields:    Translation:HumansCellsCTClinical Trials
  78. Harmon D. Treatment of advanced Ewing’s sarcoma. UpToDate, BD Rose. 2002; www.UpToDate.com.
  79. Ryan DP, Puchalski T, Supko JG, Harmon D, Maki R, Garcia-Carbonero R, Kuhlman C, Winkelman J, Merriam P, Quigley T, Jimeno J, Manola J, Demetri GD. A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. Oncologist. 2002; 7(6):531-8. PMID: 12490740.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  80. Delaney TH, Rosenberg AE, Harmon DC, Mankin HJ, Spiro I, Rosenthal D. Suit HD. Soft tissue sarcomas. Treatment of Cancer, K Sikora and P Price. 2002; 869-907.
  81. DeLaney TF, Hornicek FJ, Gebhardt MC, Ott MJ, Fischman A, Chapman PA, Rosenberg AL, Nielsen GP, Rosenthal DI, Harmon DC, Suit HD. Positron Emission Tomography (PET) in Staging and Managing Patients with Soft Tissue Sarcomas. Connective Tissue Oncology Society. 2002.
  82. Harmon D. Multiple Myeloma – Current Concepts Review. Current Opinion in Orthopedics. 2002; 13.
  83. Glaspy J, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, Rigas J, Kuter D, Harmon D, Prow D, Demetri G, Gordon D, Arseneau J, Saven A, Hynes H, Boccia R, O'Byrne J, Colowick AB. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br J Cancer. 2001 Apr; 84 Suppl 1:17-23. PMID: 11308270.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  84. Eisenburg BL, Alektiar K, Ballo M, DeLaney TF, Ettinger D, Harmon D, Harris J, Joyce M, Kraybill WG, Leider S, Lucas D, Peterson I, Pollock RE, Pritchard D, Schwartz HS, Yasko AW, Pisters PT, Patel SR, watson J. Radiation Therapy Oncology Group. Research Plan 2002-2006. Sarcoma Committee. Int J Radiat Oncol Biol Phys. 2001; 51(3 Suppl 2):53-5. PMID: 11641015.
    Citations:    Fields:    Translation:Humans
  85. Patterson A, Harmon D. Bone Tumours and Soft Tissue Sarcomas. A Core Text in Oncology, P. Johnson . 2001; 359-383.
  86. Delaney T, Spiro I, Suit H, Gebhardt M, Hornicek F, Rosenberg A, Niryousefi F, Ancukiewicz M, Harmon D. Neoadjuvant Chemotherapy and Radiotherapy for Large Extremity Soft Tissue Sarcomas. Sarcoma Nov. 2001; 5 Supp. 1, S25.
  87. Rea IM, McMaster D, Woodside JV, Young IS, Archbold GP, Linton T, Lennox S, McNulty H, Harmon DL, Whitehead AS. Community-living nonagenarians in northern ireland have lower plasma homocysteine but similar methylenetetrahydrofolate reductase thermolabile genotype prevalence compared to 70-89-year-old subjects. Atherosclerosis. 2000 Mar; 149(1):207-14. PMID: 10704633.
    Citations: 4     Fields:    Translation:HumansPHPublic Health
  88. Harmon D. Recent Experience with Chemotherapy for Angiosarcoma. Connective Tissue Oncology Society. 2000.
  89. Fidias P, Spiro I, Sobczak ML, Nielsen GP, Ruffolo EF, Mankin H, Suit HD, Harmon DC. Long-term results of combined modality therapy in primary bone lymphomas. Int J Radiat Oncol Biol Phys. 1999 Dec 01; 45(5):1213-8. PMID: 10613315.
    Citations: 21     Fields:    Translation:Humans
  90. Lintz KC, Penson RT, Cassem N, Harmon DC, Chabner BA, Lynch TJ. A staff dialogue on aggressive palliative treatment demanded by a terminally ill patient: psychosocial issues faced by patients, their families, and caregivers. Oncologist. 1999; 4(1):70-6. PMID: 10337374.
    Citations: 2     Fields:    Translation:Humans
  91. Kay PH, Hähnel R, Gunn H, Harmon D, Song J. Hypermethylation of HpaII recognition sequences within the 5' coding region of the estrogen receptor gene is not associated with estrogen receptor negativity in primary breast tumours. Anticancer Res. 1998 May-Jun; 18(3A):1709-12. PMID: 9673394.
    Citations:    Fields:    Translation:HumansCells
  92. Samuels BL, Herndon JE, Harmon DC, Carey R, Aisner J, Corson JM, Suzuki Y, Green MR, Vogelzang NJ. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Cancer. 1998 Apr 15; 82(8):1578-84. PMID: 9554537.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  93. Fidias P, Demetri G, Harmon D. Navelbine Shows Activity In Previously Treated Sarcoma Patients: Phase II Results From MGH/Dana Farber/Partner’s Cancer care Study. ASCO. 1998.
  94. Kaufman DW, Kelly JP, Anderson T, Harmon DC, Shapiro S. Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia. 1997 Dec; 38(12):1265-9. PMID: 9578520.
    Citations: 13     Fields:    Translation:Humans
  95. Spiro IJ, Gebhardt MC, Jennings LC, Mankin HJ, Harmon DC, Suit HD. Prognostic factors for local control of sarcomas of the soft tissues managed by radiation and surgery. Semin Oncol. 1997 Oct; 24(5):540-6. PMID: 9344320.
    Citations: 10     Fields:    Translation:Humans
  96. Yogelzang NJ, Herndon JE, Cirrincione C, Harmon DC, Antman KH, Corson JM, Suzuki Y, Citron ML, Green MR. Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B. Cancer. 1997 Jun 01; 79(11):2237-42. PMID: 9179072.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  97. Iacopetta BJ, Harmon D, Spagnolo DV, House AK, Kay PH. Hypermethylation of the Myf-3 gene in human colorectal cancer. Anticancer Res. 1997 Jan-Feb; 17(1A):429-32. PMID: 9066689.
    Citations: 4     Fields:    Translation:HumansCells
  98. Dupuy D, Spiro I, Harmon D. Dynamic MRI in the assessment of response to preoperative chemotherapy and radiotherapy for soft tissue sarcomas. Radiation Meetings and Connective Tissue Oncology Society. 1996.
  99. Spiro I, Suit H, Gebhardt M, Springfield D, Mankin H, Jennings A, Rosenberg A, Efird J, Harmon D. Neoadjuvant Chemotherapy and Radiotherapy for Large Soft Tissue Sarcomas. ASCO. 1996; 15: 524 (1689).
  100. Suit HD, Rosenberg AE, Harmon DC, Mankin HJ, Spiro I, Rosenthal D. Soft tissue sarcomas. Treatment of Cancer. 1995; 802-834.
  101. Greenberg DB, Goorin A, Gebhardt MC, Gupta L, Stier N, Harmon D, Mankin H. Quality of life in osteosarcoma survivors. Oncology (Williston Park). 1994 Nov; 8(11):19-25; discussion 25-6, 32, 35. PMID: 7826837.
    Citations: 10     Fields:    Translation:Humans
  102. Harmon DC, Nielsen GP. A 55 year old man with a paraspinal mass and a history of radiation treatment of a testicular tumor. Case records of the Massachusetts General Hospital. 1994; 331:1079-1085.
  103. Kaufman DW, Kelly JP, Johannes CB, Sandler A, Harmon D, Stolley PD, Shapiro S. Acute thrombocytopenic purpura in relation to the use of drugs. Blood. 1993 Nov 01; 82(9):2714-8. PMID: 8219224.
    Citations: 15     Fields:    Translation:Humans
  104. Gerard EL, Ferry JA, Amrein PC, Harmon DC, McKinstry RC, Hoppel BE, Rosen BR. Compositional changes in vertebral bone marrow during treatment for acute leukemia: assessment with quantitative chemical shift imaging. Radiology. 1992 Apr; 183(1):39-46. PMID: 1549692.
    Citations: 7     Fields:    Translation:Humans
  105. Samuels B, Green Man, Harmon D, Aisner J, Herndon J, Mason-Coughlin K+, Vogelzang N. Dihydro-5-Azacytidine and Cisplatin (DDP) in Malignant Mesothelioma. ASCO. 1992.
  106. Harmon DC. The Leukemias. Hematology. 1991; 399-418.
  107. Mankin HJ, Willett CG, Harmon DC. Malignant Tumors of Bone. ACS Clinical Oncology. 1991; 355-376.
  108. Harmon D, Vogelzang J, Roboz M, Goutsou K, Antman K, Coughlin K, Green MR. Dihydro-5-Azacytidine (DHAC) in Malignant Mesothelioma (MESO) Using Serum Hyaluronic Acid (SHA) as a Tumor Marker: A Phase Trial of the CALGB. ASCO. 1991; 10:351(1248).
  109. Pettit CK, Zukerberg LR, Gray MH, Ferry JA, Rosenberg AE, Harmon DC, Harris NL. Primary lymphoma of bone. A B-cell neoplasm with a high frequency of multilobated cells. Am J Surg Pathol. 1990 Apr; 14(4):329-34. PMID: 2321697.
    Citations: 12     Fields:    Translation:HumansCells
  110. Harmon D. Secondary bone tumors, myeloma, cryoglobulinemia, and paraproteinemias. Curr Opin Rheumatol. 1990 Feb; 2(1):111-4. PMID: 2223434.
    Citations:    Fields:    Translation:Humans
  111. Harmon DC. Chemotherapy. Tumors of The Spine: Diagnosis and Clinical Management, Schiller and D. Rosenthal . 1990; 152-153.
  112. Suit HD, Rosenberg AE, Harmon DC, Mankin HJ, Wood WC, Rosenthal D. Soft tissue sarcomas. Treatment of Cancer, K Sikora and K Halnan. 1990; 657-678.
  113. Medeiros LJ, Harmon DC, Linggood RM, Harris NL. Immunohistologic features predict clinical behavior of orbital and conjunctival lymphoid infiltrates. Blood. 1989 Nov 01; 74(6):2121-9. PMID: 2804350.
    Citations: 6     Fields:    Translation:HumansCells
  114. Sharpe RJ, Kadin ME, Harmon DC, Imber MJ, Anderson RR. Complete resolution of Kaposi's sarcoma with systemic etretinate therapy in a patient with mycosis fungoides. J Am Acad Dermatol. 1989 Jun; 20(6):1123-4. PMID: 2754062.
    Citations: 3     Fields:    Translation:Humans
  115. Young N, Griffith P, Brittain E, Elfenbein G, Gardner F, Huang A, Harmon D, Hewlett J, Fay J, Mangan K, et al. A multicenter trial of antithymocyte globulin in aplastic anemia and related diseases. Blood. 1988 Dec; 72(6):1861-9. PMID: 3058228.
    Citations: 14     Fields:    Translation:HumansCTClinical Trials
  116. de Paula U, Suit HD, Harmon D. Adjuvant chemotherapy in clinical stage M0 sarcoma of soft tissue. Cancer. 1988 Nov 01; 62(9):1907-11. PMID: 3048644.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  117. Sailer SL, Harmon DC, Mankin HJ, Truman JT, Suit HD. Ewing's sarcoma: surgical resection as a prognostic factor. Int J Radiat Oncol Biol Phys. 1988 Jul; 15(1):43-52. PMID: 3391827.
    Citations: 6     Fields:    Translation:Humans
  118. Suit HD, Mankin HJ, Wood WC, Gebhardt MC, Harmon DC, Rosenberg A, Tepper JE, Rosenthal D. Treatment of the patient with stage M0 soft tissue sarcoma. J Clin Oncol. 1988 May; 6(5):854-62. PMID: 3367188.
    Citations: 28     Fields:    Translation:Humans
  119. Suit HD, Tepper JE, Mankin HJ, Truman JT, Wood WC, Harmon DC, Schiller AL, Rosenberg A. Sarcomas of soft tissue and bone. Clinical Radiation Oncology: Indications, Techniques and Results, C.C. Wang . 1988; 331-339.
  120. Wilson RE, Wood WC, Lerner HL, Antman K, Amato D, Corson JM, Proppe K, Harmon D, Carey R, Greenberger J, et al. Doxorubicin chemotherapy in the treatment of soft-tissue sarcoma. Combined results of two randomized trials. Arch Surg. 1986 Nov; 121(11):1354-9. PMID: 3535741.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  121. Harmon DC, Stossel TP. Neutropenia. Conn's Current Therapy, R.E. Rakel. 1986; 289-290.
  122. Weitzman SA, Stossel TP, Harmon DC, Daniels G, Maloof F, Ridgway EC. Antineutrophil autoantibodies in Graves' disease. Implications of thyrotropin binding to neutrophils. J Clin Invest. 1985 Jan; 75(1):119-23. PMID: 3838096.
    Citations: 8     Fields:    Translation:HumansCells
  123. Koh HK, Sober AJ, Harmon DC, Lew RA, Carey RW. Adjuvant therapy of cutaneous malignant melanoma: a critical review. Med Pediatr Oncol. 1985; 13(5):244-60. PMID: 3897817.
    Citations: 1     Fields:    Translation:HumansCells
  124. Harmon DC. The Leukemias. Hematology, W.S. Beck. 1985; 323-338.
  125. Harmon DC, Weitzman SA, Stossel TP. The severity of immune neutropenia correlates with the maturational specificity of antineutrophil antibodies. Br J Haematol. 1984 Oct; 58(2):209-15. PMID: 6383453.
    Citations: 5     Fields:    Translation:HumansCells
  126. Harmon DC, Aisenberg AC, Harris NL, Dallow RL, Linggood RM, Wilkes BM. Lymphocyte surface markers in orbital lymphoid neoplasms. J Clin Oncol. 1984 Jul; 2(7):856-60. PMID: 6376724.
    Citations:    Fields:    Translation:HumansCells
  127. Tepper JE, Suit HD, Wood WC, Proppe KH, Harmon D, McNulty P. Radiation therapy of retroperitoneal soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 1984 Jun; 10(6):825-30. PMID: 6735766.
    Citations: 18     Fields:    Translation:Humans
  128. Antman K, Suit H, Amato D, Corson J, Wood W, Proppe K, Harmon D, Carey R, Greenberger J, Blum R, et al. Preliminary results of a randomized trial of adjuvant doxorubicin for sarcomas: lack of apparent difference between treatment groups. J Clin Oncol. 1984 Jun; 2(6):601-8. PMID: 6374055.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  129. Weitberg AB, Harmon DC. Autoimmune neutropenia, hemolytic anemia, and reticulocytopenia in Hodgkin's disease. Ann Intern Med. 1984 May; 100(5):702-3. PMID: 6546845.
    Citations:    Fields:    Translation:HumansCells
  130. Joyce MJ, Harmon DC, Mankin HJ, Suit HD, Schiller AL, Truman JT. Ewing's sarcoma in female siblings. A clinical report and review of the literature. Cancer. 1984 May 01; 53(9):1959-62. PMID: 6704922.
    Citations: 9     Fields:    Translation:Humans
  131. Harris NL, Pilch BZ, Bhan AK, Harmon DC, Goodman ML. Immunohistologic diagnosis of orbital lymphoid infiltrates. Am J Surg Pathol. 1984 Feb; 8(2):83-91. PMID: 6367504.
    Citations: 4     Fields:    Translation:Humans
  132. Schooley RT, Densen P, Harmon D, Felsenstein D, Hirsch MS, Henle W, Weitzman S. Antineutrophil antibodies in infectious mononucleosis. Am J Med. 1984 Jan; 76(1):85-90. PMID: 6318560.
    Citations: 4     Fields:    Translation:HumansCells
  133. Antman K, Amato D, Lerner H, Suit H, Corson J, Wood W, Proppe K, Harmon DC, Carey R,Greenberger J, Wilson R. Pooled results of two randomized trial adjuvant doxorubicin for sarcomas . Adjuvant chemotherapy of Cancer IV, S. Jones and S. Salmon. 1984; 611-620.
  134. Harmon DC, Harris NL. A 75-year-old diabetic woman with an osteolytic lesion of the spine. Case records of the Massachusetts General Hospital. 1984; 311:455-462.
  135. Harmon DC, Weitzman SA, Stossel TP. A slide test for detecting neutrophil-associated complement components. Transfusion. 1983 Mar-Apr; 23(2):131-4. PMID: 6340269.
    Citations:    Fields:    Translation:HumansCells
  136. Antman K, Wood W, Price K, Amato D, Corson J, Suit H, Proppe K, Harmon D, Carey R, Greenberger J, Wilson R. A comparison of randomized versus concurrent controls. AACR. 1983; #577.
  137. Antman K, Suit H, Amato D, Corson J, Wood W, Proppe K, Harmon D, Carey R, Greenberger J, Blum R, Wilson R. Preliminary results of a randomized trial of adjuvant adriamycin for sarcomas. ASCO. 1983; #236.
  138. Cosimi AB, Peters C, Harmon D, Ellman L. Treatment of severe aplastic anemia with a prolonged course of anti-thymocyte globulin. Transplant Proc. 1982 Dec; 14(4):761-4. PMID: 6984802.
    Citations:    Fields:    Translation:HumansCells
  139. Harmon DC. Weitzman S, Stossel TP. The clinical spectrum of auto-immune neutropenia is determined by the selectivity of anti-neutrophil antibodies. Blood. 1981; 58 Supp.1:89a.
  140. Harmon DC, Weitzman SA, Stossel TP. A staphylococcal slide test for detection of antineutrophil antibodies. Blood. 1980 Jul; 56(1):64-9. PMID: 6992888.
    Citations: 2     Fields:    Translation:HumansCells
  141. Harmon DC, Demirjian Z, Ellman L, Fischer JE. Disseminated intravascular coagulation with the peritoneovenous shunt. Ann Intern Med. 1979 May; 90(5):774-6. PMID: 434678.
    Citations: 13     Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Harmon's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (475)
Explore
_
Co-Authors (78)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.